Articles
- Facial feminization surgery
- Dopamine agonists
- Sex reassignment surgery
- Imaging of the dopaminergic system in differential diagnosis of dementia.
- Dynamics of dopamine and norepinephrine contents in the dorsal hippocampus of rats during immunization with dopamine conjugate.
- Lobelia chinensis
- Selegiline-wikipedia spam
- What is the most important information I should know about selegiline?
- What is Selegiline?
- Selegiline patch doesn't alter sexual function
- Important Warning
- Inexpensive Drug Effective in Early Parkinson's
- Selegiline Treatment Report
- Safety of nicotine: the smoke causes the harm
- USPSYCH: Depression Remission Rates Remain Low, But There's Hope
- Aging Cat's Caterwauls Could Be a Sign of Dementia
Inexpensive Drug Effective in Early Parkinson's
THURSDAY, Aug. 12 (HealthDayNews) -- An inexpensive drug called selegiline may be one of the best treatments during the early stages of Parkinson's disease, according to a study in the British Medical Journal.
However, the authors of this new study say this link between selegiline and high death rates was likely a chance finding, and the drug could be among the most effective and inexpensive ways to treat early Parkinson's disease.
The researchers based their conclusion on a review of 17 trials comparing MAOBIs with a placebo or another commonly used Parkinson's drug called levodopa. They found that MAOBIs reduced disability and problems with movement, and the need for levodopa, without substantial side effects or increased risk of death.
Further, large-scale, long-term trials comparing selegiline with other drugs and assessing Parkinson's disease patients' quality of life measures need to be done, the authors wrote.